PINNED
PINNED
Pharma Horizons: leading-edge formulation
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
List view / Grid view
Articles
The significance and detection of VBNC microorganisms
23 May 2007 | By Dr Paul Newby, Team Leader, Pharmaceutical Microbiology, GlaxoSmithKline
The purpose of this article is to assess the potential significance of Viable but Non Culturable (VBNC) microorganisms in the pharmaceutical industry; consideration is given to the definition of the VBNC state, current methods for the detection of such organisms are outlined and potentially significant new methods, which may impact…
Inducible systemic RNA silencing in Caenorhabditis elegans
27 March 2007 | By Lisa Timmons, Department of Molecular Biosciences, The University of Kansas, Hiroaki Tabara, University of Tokushima, Japan, Craig C. Mello, Howard Hughes Medical Institutes and Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts and Andrew Fire, Stanford School of Medicine, Stanford University
Introduction of double-stranded RNA (dsRNA) can elicit a gene-specific RNA interference response in a variety of organisms and cell types. In many cases, this response has a systemic character in that silencing of gene expression is observed in cells distal from the site of dsRNA delivery. The molecular mechanisms underlying…
Biomarkers in neurodegenerative diseases
27 March 2007 | By Claudio Carini, MD,PhD,FRCPath, F. VP of Translational Medicine, MDS Pharma
Biomarkers are useful characteristics to evaluate disease progress and targets of therapeutic agents. They are objectively measured and obtained by non-invasive procedures collecting readily accessible matrixes (Blood, CSF). Biomarkers should be easy to detect, specific and reproducible. Most importantly when detected early in the course of a disease they should…
55th ASMS Conference on Mass Spectrometry
27 March 2007 | By EPR
The American Society for Mass Spectrometry (ASMS) was formed in 1969 to promote and disseminate knowledge of mass spectrometry and allied topics. Membership includes over 7,000 scientists involved in research and development. ASMS sponsors the Annual Conference on Mass Spectrometry that is attended by almost 6,000 scientists.
Stathmin immobilisation on a chip using an oligo-cysteine tag
27 March 2007 | By Kazuyuki Nakamura, M.D., Ph.D., Professor and Chairman, Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine
Protein chip technology is essential for high through-put functional proteomics. In this review the development of a novel protein tag consisting of five tandem cysteine repeats (Cys-tag) at C-terminus of proteins which was covalently attached to the surface of a maleimide-modified diamond-like carbon-coated silicon chip substrate is described.
Neuronal morphology screening as a tool in neuroscience drug discovery
27 March 2007 | By Myles Fennell and John Dunlop, Neuroscience Discovery Research, Wyeth Research
High content screening (HCS) has now become integrated into all aspects of drug discovery from target identification and validation to hit generation and lead optimisation through to toxicological profiling. In neuroscience, the ability to perform automated neurite outgrowth and neuronal morphology screening has been a significant driver of HCS implementation.…
The 8th Congress of the French Neuroscience Society
27 March 2007 | By EPR
The 8th Congress of the French Neuroscience Society will be held in Montpellier, France on May 22-25, 2007. For the first time, the meeting is organised together with another neuroscience society, the Spanish Neuroscience Society.
Novel strategies for antidepressant drug discovery
27 March 2007 | By Chad E. Beyer, PhD, Discovery Neuroscience, Wyeth Research
Despite marked advances in our understanding of chemical transmission, many of the complex processes, namely, our appreciation of the varying roles of neurochemicals in disease etiology, are still being investigated. To aid in this exploration and to monitor the extracellular levels of neurochemicals in living tissue systems, techniques such as…
HTS technologies to facilitate chemical genomics
27 March 2007 | By Douglas S. Auld, James Inglese, Ajit Jadhav and Christopher P. Austin, NIH Chemical Genomics Center, National Institutes of Health, Bethesda, G.Sitta Sittampalam, Chahrzad Montrose-Rafizadeh and James E. Mcgee, Lead Generation & Lead Optimization Biology, Discovery Chemistry Research & Technology and Philip W. Iversen, Global Discovery & Development Statistics, Eli Lilly & Company
Industrial scale technologies developed and applied within the pharmaceutical industry for the purpose of drug discovery have recently been adopted by many research laboratories for the purpose of facilitating chemical genomics. Taking full advantage of these technologies will require education in high-throughput screening assay systems as well as new methods…
Industry Insight: United they stand
27 March 2007 | By EPR
Late last year, Thermo Electron and Fisher Scientific merged to become Thermo Fisher Scientific, Inc., the world leader in serving science. European Pharmaceutical Review spoke to Marc Casper, vice president of Thermo Fisher Scientific and president of its analytical technologies group to discover the impact this has had on the…
10th Anniversary of MIPTEC 2007 – The leading European Event for Drug Discovery Technologies
27 March 2007 | By EPR
In the last decade, MipTec has evolved as the leading event in Europe on enabling technologies in the drug discovery process with its scientific programme and the accompanying exhibition. The conference is ideally suited for both specialists and newcomers to the field and gives everyone an excellent opportunity to gain…
Calorimetry for polymorph detection
27 March 2007 | By Simon Gaisford PhD., School of Pharmacy, University of London and Michael AA O’Neill PhD., Department of Pharmacy and Pharmacology, University of Bath
Characterising the properties of a material, understanding how these properties change in relation to local environment and quantifying potential interactions with other species are facets central to any drug development programme. Not understanding and, more importantly, not controlling these factors can have serious consequences for a pharmaceutical, from irreproducible processing…
PAT and scalable automation for bioprocess control and monitoring
27 March 2007 | By Joydeep Ganguly, PAT Group Lead and Gerrit Vogel, Senior Engineering Manager, Talecris Biotherapeutics
This case study provides a comprehensive look at Talecris1 Biotherapeutics’ approach to PAT and automation followed by examples of PAT deployed on a bioprocess. It introduces the concept of integrated and scalable automation, provides a comparison of automation concepts and explains how the selected automation effectively supports initiatives such as…
Advancing the science of drug discovery
27 March 2007 | By EPR
Montréal, one of Canada’s most vibrant and beautiful cities, provides an idyllic setting for the Society of Biomolecular Sciences’ 13th Annual Conference & Exhibition. The 2007 scientific program encompasses many of the core themes from previous SBS conferences, including target biology and screening strategies, as well as new instrumentation and…
Cleanroom standards
27 March 2007 | By John Neiger, Technical writer and consultant
It is some years since the ISO 14644 and 14698 series of international cleanroom standards started taking over from national standards. Early parts are already undergoing their statutory five-year reviews; other parts have only recently been published and new parts are still being written.
